Alipay+ E-Wallet Partnerships Power iQIYI’s Fast Asia Expansion
19.4.2023 12:06:00 EEST | Business Wire | Press release
Popular Asian e-wallets are helping iQIYI, a leading international streaming platform, accelerate its expansion through Alipay+ to help digital and entertainment (D&E) platforms reach young middle-class consumers looking for quality online video content.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005470/en/
More than 1 million consumers outside the Chinese mainland used Alipay+ partner e-wallets for subscription payments on iQIYI international app in 2022 (Photo: Business Wire)
Introduced by Ant Group in 2020, Alipay+ is a suite of cross-border digital payment, marketing and merchant digitalization solutions connecting global brands with mobile-savvy consumers worldwide, aimed at enabling businesses, particularly small and medium-sized enterprises, to process a wide range of mobile payment methods and reach more than 1 billion regional and global consumers.
Starting in 2021, iQIYI utilizes Alipay+ marketing solutions, such as Alipay+ Rewards and cashier-based marketing service, to reach potential consumers and improve transaction conversion rates in key markets. Developed by Alipay+ and partner e-wallets, Alipay+ Rewards is a new digital marketing platform that helps global brands engage better with consumers worldwide by offering incentives and exclusive services.
In 2022, more than 1 million consumers outside the Chinese mainland, mostly in Southeast Asia, used Alipay+ partner e-wallets, including TrueMoney (Thailand), GCash (The Philippines), DANA (Indonesia), Touch ’n Go eWallet (Malaysia) and Kakao Pay (South Korea) to pay for subscriptions or content on iQIYI’s international app.
In addition to these alternative payment methods, since 2023, Alipay+ has started offering customized marketing solutions through Alipay+ Rewards program to enable merchant partners to expand its market outreach efforts. On iQIYI’s international app, the number of new users making subscription payments through GCash, DANA and Touch ’n Go eWallet have increased respectively by 100 percent, 90 percent and 50 percent in March 2023, compared with the end of 2022.
The global over-the-top (OTT) market is expected to reach US$1,251 billion by 2027, representing a CAGR of 30 percent during 2021-20271. iQIYI ranks fifth among OTT platforms globally, and was named the top Asian OTT to watch Chinese-language, Thai and Malay dramas across major SEA markets.2
On April 18 in Bangkok, iQIYI kicked off its latest subscriber campaign for Southeast Asia by inviting hundreds of local fans to interact with leading casts of a popular TV series on its platform. The event was co-hosted by Alipay+ as one of its key e-wallet partners, TrueMoney, is popular in Thailand.
In April 2023, AlipayHK, the largest active e-wallet in Hong Kong SAR, China, became the latest Alipay+ partner wallet to support payment on iQIYI International App.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing solutions offered by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
About iQIYI
iQIYI, Inc. is a leading provider of online entertainment video services in China. It combines creative talent with technology to foster an environment for continuous innovation and the production of blockbuster content. It produces, aggregates and distributes a wide variety of professionally produced content, as well as a broad spectrum of other video content in a variety of formats. The Company distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. iQIYI attracts a daily subscriber base of more than 100 million, and its diversified monetization model includes membership services, online advertising services, content distribution, online games, IP licensing, talent agency, online literature, etc.
1
https://www.researchandmarkets.com/reports/5633245/over-the-top-ott-market-global-industry
2
https://www.screendaily.com/features/unpacking-the-recent-turnaround-success-of-chinese-streamer-iqiyi/5180170.article
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005470/en/
Contact information
Media Inquiries
Li Tao
Ant Group
tao.l@antgroup.com
Aggie Yu
iQIYI
aggieyu@qiyi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom